10037341 - GAU: 1636

Receipt date: 09/24/2009 Page 1 of 1

Form PTO-1449 Substitute U.S. Department of Commerce	Application Number	10/03/,341	
Patent and Trademark Office	Filing Date	January 4, 2	002
	First Named Inventor	David Baltim	ore
INFORMATION DISCLOSURE STATEMENT	Art Unit	1636	
Use several sheets if necessary)	Examiner Name	C. Hibbert	
I		75723-	
SEP 2 4 2009	Attorney Docket No.	ZA/JPW/GJG/CS	
SEP 3 T B			
NON PATENT LITERATURE DOC	CUMENTS		
Include name of the author (in CAPITAL LETTERS), title of the linitials No. 1 (book, magazine, journal, serial, symposium, catalog, etc.) date, pand/or country where put	age(s), volume-issue nui	riate), title of the item mber(s), publisher, city	T ²
Order issued August 21, 2009 in the captioned ARIAD Pharmaceuticals, In and Company, U.S. Court of Appeals Docket No. 2008-1248; and	c., et al. v	. Eli Lilly	
/C.H./ Decision issued June 1, 2009 in the captioned Amgen, Inc., et al. v. AR Inc., et al., U.S. Court of Appeals Circuit, Docket No. 2009-1023.	IAD Pharmace	uticals,	
			-
			
			L
Catherine Hibbert/ DATE CONSIDERED	06/08/2010		

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a checkmark here if English language Translation is attached.

Applicants: David Baltimore, et al.

Serial No.: 10/037,341 Filed: January 4, 2002

Exhibit A